Polomar Health Services, Inc. (PMHS) stock
Close on Oct 19, 2026Market cap $3.37MP/E –Yield –
Polomar Health Services, Inc. grew revenue 7688.8% to $3.17M over the twelve months to Jun 30, 2026. At the latest close the market valued the company at $3.37M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $3.37M
- P/E ratio
- –
- Price to sales
- 1.06
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $3.17M
- Net income
- -$9.46M
- EPS, diluted
- -$0.34
- Book value per share
- -$0.04
- Diluted shares
- 28M
Trading
- Previous close
- $0.13
- Open
- $0.10
- Day's range
- $0.10 – $0.12
- Volume
- 15,000
- Average volume (20 days)
- 17,402
Market cap history
Month-end market cap since 2023, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Oct 19, 2026. The S&P 500 is measured by the SPY fund.
| Period | PMHS | S&P 500 | Difference | PMHS per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -40.6% | +0.6% | −41.2 pts | ||
| 3 months | +1.7% | +3.4% | −1.7 pts | ||
| Year to date | -85.0% | +13.3% | −98.3 pts | ||
| 1 year | -40.0% | +16.6% | −56.6 pts | ||
| 3 years | -90.8% | +86.4% | −177.1 pts | -54.8% | +23.1% |
| 5 years | -99.9% | +81.9% | −181.8 pts | -76.1% | +12.7% |
| 10 years | -97.0% | +318.9% | −415.9 pts | -29.6% | +15.4% |
Five years at a glance
Fiscal years 2021 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
About Polomar Health Services
Pharmaceutical Preparations
Polomar Health Services, Inc. operates a retail compounding pharmacy business through its subsidiary, Polomar Specialty Pharmacy, LLC. The company specializes in manufacturing and dispensing custom prescription formulations, including dermatological topical treatments and sterile injectable GLP-1 receptor agonists used for weight management, alongside erectile dysfunction medications. In addition to compounding sterile injectables on-site, it sources non-sterile inhaled and sublingual drug formulations from contract manufacturers and outsourcing facilities. The business serves patients directly through healthcare provider prescriptions and provides wholesale fulfillment services to third-party telehealth platforms. It also plans to market weight loss therapies through its proprietary online platform, SlimRx.
Company profile, executives and historyPolomar Health Services stock: common questions
What is Polomar Health Services's stock price?
PMHS closed at $0.12 on Oct 19, 2026, down 4.00% on the day.
What is Polomar Health Services's market cap?
Polomar Health Services was worth $3.37M at the close on Oct 19, 2026: the share price times the diluted shares outstanding.
What is PMHS's P/E ratio?
Polomar Health Services lost money over the twelve months to Jun 30, 2026 (diluted EPS -$0.34), so it has no meaningful P/E ratio.
How much revenue does Polomar Health Services make?
Polomar Health Services reported revenue of $3.17M for the twelve months to Jun 30, 2026, up 7688.8% from a year earlier.
Does Polomar Health Services pay a dividend?
No. Polomar Health Services has not paid a cash dividend over the last twelve months.
How has PMHS stock performed over the past year?
Including dividends, PMHS returned -40.0% over the past year, against +16.6% for the S&P 500.
Who are Polomar Health Services's competitors?
Companies most similar to Polomar Health Services by business, industry and size include CPHI, TXMD, NRXP, LPCN, PTPI.
See a number that looks wrong?